The economic burden of metastatic breast cancer in Spain.

Autor:	Bermejo de Las Heras B; Hospital Clinico Universitario de Valencia, Valencia, Spain., Cortes Ramon Y Cajal J; Madrid & Vall d'Hebron Institute of Oncology (VHIO), University Hospital, Barcelona, Spain., Galve Calvo E; Basurto Hospital, Bilbao, Spain., de la Haba Rodriguez J; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain., Garcia Mata J; Xerencia de Xestión Integrada de Ourense, Complexo Hospitalario Universitario de Ourense, Verín e o Barco de Valdeorras, Spain., Moreno Anton F; Oncology Department, Hospital Clíinico San Carlos, Madrid, Spain., Pelaez Fernandez I; Hospital Universitario de Cabueñes at Gijón, Gijon, Spain., Rodriguez-Lescure A; Hospital General Universitario de Elche, Alicante, Spain.; Spain and Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain., Rodriguez Sanchez CA; Hospital Universitario de Salamanca - IBSAL, Salamanca, Spain., Ruiz-Borrego M; Hospital Universitario Virgen del Rocío, Seville, Spain., Remak E; Evidera, Budapest, Hungary., Barra M; Evidera, Budapest, Hungary., Rivero M; Pfizer S.A., Madrid, Spain., Soto Alvarez J; Pfizer S.A., Madrid, Spain.
Jazyk:	angličtina
Zdroj:	European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2020 Jan; Vol. 27 (1), pp. 19-24. Date of Electronic Publication: 2018 Jul 30.
DOI:	10.1136/ejhpharm-2017-001453
Abstrakt:	Objectives: The study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years. Methods: An incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles. Results: The incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2-/HR+, 520 HER2+/HR+, 324 HER2+/HR-, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2-/HR+, 2.82 years for HER2+/HR- and shortest mean survival of 1.74 years for triple negative patients. The total costs were €469,92,731 for the overall population, €190,079,787 for the HER2-/HR+, €151,045,260 for the HER2+/HR+, €80,827,171 for the HER2+/HR- and €47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were €160,642 on average, €120,664 for HER2-/HR+, €290,346 for HER2+/HR+, €249,152 for HER2+/HR-and €94,572 for triple negative patients over 5 years. Conclusions: The economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2-/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs. Competing Interests: Competing interests: None declared. (© European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu